Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02987166
Title HDCRT Plus Pembrolizumab in Advanced Malignancies (UVA-AM-001)
Acronym UVA-AM-001
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors James Larner, MD
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.